Skip Navigation
Skip to contents

JMD : Journal of Movement Disorders

OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > Browse Articles > Author index
Search
Doo-Sup Choi 1 Article
Emerging Nondopaminergic Medications for Parkinson’s Disease: Focusing on A2A Receptor Antagonists and GLP1 Receptor Agonists
Pei Shang, Matthew Baker, Samantha Banks, Sa-Ik Hong, Doo-Sup Choi
J Mov Disord. 2021;14(3):193-203.   Published online August 18, 2021
DOI: https://doi.org/10.14802/jmd.21035
  • 7,067 View
  • 216 Download
  • 8 Web of Science
  • 10 Crossref
AbstractAbstract PDF
Parkinson’s disease (PD) is a severe neurodegenerative disease characterized by classic motor features associated with the loss of dopaminergic neurons and appearance of Lewy bodies in the substantia nigra. Due to the complexity of PD, a definitive diagnosis in the early stages and effective management of symptoms in later stages are difficult to achieve in clinical practice. Previous research has shown that colocalization of A2A receptors (A2AR) and dopamine D2 receptors (D2R) may induce an antagonistic interaction between adenosine and dopamine. Clinical trials have found that the A2AR antagonist istradefylline decreases dyskinesia in PD and could be used as an adjuvant to levodopa treatment. Meanwhile, the incretin hormone glucagon-like peptide 1 (GLP1) mainly facilitates glucose homeostasis and insulin signaling. Preclinical experiments and clinical trials of GLP1 receptor (GLP1R) agonists show that they may be effective in alleviating neuroinflammation and sustaining cellular functions in the central nervous system of patients with PD. In this review, we summarize up-to-date findings on the usefulness of A2AR antagonists and GLP1R agonists in PD management. We explain the molecular mechanisms of these medications and their interactions with other neurotransmitter receptors. Furthermore, we discuss the efficacy and limitations of A2AR antagonists and GLP1R agonists in clinical practice.

Citations

Citations to this article as recorded by  
  • Effects of Intracerebral Aminophylline Dosing on Catalepsy and Gait in an Animal Model of Parkinson’s Disease
    Érica de Moraes Santos Corrêa, Gustavo Christofoletti, Albert Schiaveto de Souza
    International Journal of Molecular Sciences.2024; 25(10): 5191.     CrossRef
  • Purinergic signaling: A gatekeeper of blood-brain barrier permeation
    Yuemei Wang, Yuanbing Zhu, Junmeng Wang, Longcong Dong, Shuqing Liu, Sihui Li, Qiaofeng Wu
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Locomotor Behavior and Memory Dysfunction Induced by 3-Nitropropionic Acid in Adult Zebrafish: Modulation of Dopaminergic Signaling
    Melissa Talita Wiprich, Rafaela da Rosa Vasques, Darlan Gusso, Gabriel Rübensam, Luiza Wilges Kist, Mauricio Reis Bogo, Carla Denise Bonan
    Molecular Neurobiology.2023;[Epub]     CrossRef
  • Strategies for Drug Delivery into the Brain: A Review on Adenosine Receptors Modulation for Central Nervous System Diseases Therapy
    Mercedes Fernandez, Manuela Nigro, Alessia Travagli, Silvia Pasquini, Fabrizio Vincenzi, Katia Varani, Pier Andrea Borea, Stefania Merighi, Stefania Gessi
    Pharmaceutics.2023; 15(10): 2441.     CrossRef
  • Restoring autophagic function: a case for type 2 diabetes mellitus drug repurposing in Parkinson’s disease
    Marco Greco, Anas Munir, Debora Musarò, Chiara Coppola, Michele Maffia
    Frontiers in Neuroscience.2023;[Epub]     CrossRef
  • Adenosine receptors: Emerging non-opioids targets for pain medications
    Soo-Min Jung, Lee Peyton, Hesham Essa, Doo-Sup Choi
    Neurobiology of Pain.2022; 11: 100087.     CrossRef
  • A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
    Andrea Spinaci, Catia Lambertucci, Michela Buccioni, Diego Dal Ben, Claudia Graiff, Maria Cristina Barbalace, Silvana Hrelia, Cristina Angeloni, Seyed Khosrow Tayebati, Massimo Ubaldi, Alessio Masi, Karl-Norbert Klotz, Rosaria Volpini, Gabriella Marucci
    Molecules.2022; 27(8): 2386.     CrossRef
  • Pathophysiological Role and Medicinal Chemistry of A2A Adenosine Receptor Antagonists in Alzheimer’s Disease
    Stefania Merighi, Pier Andrea Borea, Katia Varani, Fabrizio Vincenzi, Alessia Travagli, Manuela Nigro, Silvia Pasquini, R. Rama Suresh, Sung Won Kim, Nora D. Volkow, Kenneth A. Jacobson, Stefania Gessi
    Molecules.2022; 27(9): 2680.     CrossRef
  • Modulation of adenosine signaling reverses 3-nitropropionic acid-induced bradykinesia and memory impairment in adult zebrafish
    Melissa Talita Wiprich, Stefani Altenhofen, Darlan Gusso, Rafaela da Rosa Vasques, Rodrigo Zanandrea, Luiza Wilges Kist, Mauricio Reis Bogo, Carla Denise Bonan
    Progress in Neuro-Psychopharmacology and Biological Psychiatry.2022; 119: 110602.     CrossRef
  • A Focus on Astrocyte Contribution to Parkinson’s Disease Etiology
    Giselle Prunell, Silvia Olivera-Bravo
    Biomolecules.2022; 12(12): 1745.     CrossRef

JMD : Journal of Movement Disorders Twitter